Neoleukin
Mr. Palekar’s career in the biopharmaceuticals industry spans more than 30 years. He joined 89Bio in 2018 as the company’s first Chief Executive Officer. Prior to that, he served as president and CEO of Avanir Pharmaceuticals after a series of leadership roles in commercial and operations. Prior to Avanir, Rohan served as the Chief Commercial Officer of Medivation. Earlier in his career, Rohan spent 16 years at Johnson & Johnson in various senior commercial and strategic management roles including worldwide VP of immunology. Mr. Rohan holds an MBA from the Amos Tuck School of Business Administration at Dartmouth College, a Chartered Accountant certification and degrees in law and accounting from the University of Bombay.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Neoleukin
Neoleukin Therapeutics emerged from the University of Washington Institute for Protein Design in January of 2019. They are creating next generation immunotherapies using breakthrough de novo protein design technology.